JCO

Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial

Retrieved on: 
Monday, November 6, 2023
Science, Breast, Report, ESMO, Progression-free survival, Therapy, Metastatic breast cancer, RL, Congress, European Society for Medical Oncology, Cyclin-dependent kinase 4, Conference, Breast cancer, Research, Cancer, Estrogen receptor alpha, Poster, JCO, Sheba Medical Center, ESR1, Fuchs, Prognosis, RM, Oncology, Estrogen, Clinical Cancer Research, Mortality, Patient, Fulvestrant, Mutation, Pharmaceutical industry, Medical imaging, Liquor, Woman, Incidence

The open-access case report, “ Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation ,” details a patient result that was reported during Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1, NCT03781063) study.

Key Points: 
  • The open-access case report, “ Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation ,” details a patient result that was reported during Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1, NCT03781063) study.
  • The case was previously presented as a poster and brief talk at the annual Metastatic Breast Cancer Research Conference in September 2022.
  • Topline results from the ELAINE-1 trial, including this patient, were reported at the European Society for Medical Oncology (ESMO) Congress 2022.
  • 5Jeselsohn R, De Angelis C, Brown M, et al: The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.

Spire Global Awarded Subcontract by Riverside Research for United States Space Force Space Domain Awareness Program

Retrieved on: 
Tuesday, October 24, 2023
Aerospace, Manufacturing, Satellite, Data Management, Technology, Space force, Orientation, USSF, SPIR, Safety, Spire Global, LEO, NYSE, Badges of the United States Space Force, Joint Task Force–Space Defense, JCO, Communications satellite, Spire

Spire Global, Inc. (NYSE: SPIR) (“Spire” or “the Company”), a leading global provider of space-based data, analytics and space services, today announced it was awarded a subcontract by Riverside Research, an advanced research nonprofit, to provide star tracker imagery as part of the Data Exploitation and Enhanced Processing for Space Domain Awareness (DEEP-SDA) project on behalf of the United States Space Force (USSF).

Key Points: 
  • Spire Global, Inc. (NYSE: SPIR) (“Spire” or “the Company”), a leading global provider of space-based data, analytics and space services, today announced it was awarded a subcontract by Riverside Research, an advanced research nonprofit, to provide star tracker imagery as part of the Data Exploitation and Enhanced Processing for Space Domain Awareness (DEEP-SDA) project on behalf of the United States Space Force (USSF).
  • Spire will be the leading provider of star tracker imagery, and all data will be used in direct support of the Joint Task Force-Space Defense Commercial Operations Cell (JCO), a specialized Space Force unit that works with commercial space data.
  • "As activity in space increases, monitoring it is critical for the safety, security and sustainability of our space domain,” said Chuck Cash, vice president of federal sales at Spire.
  • “With our star tracker imagery, Riverside Research can more accurately provide space domain awareness for the JCO and USSF.”
    Star trackers are optical sensors utilized on satellites to precisely determine and maintain their orientation in space.

First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO

Retrieved on: 
Tuesday, October 24, 2023
TKI, Bevacizumab, Patient, Pemetrexed, Arm, PC, NSCLC, Carboplatin, CDX, ESMO, Progression-free survival, III, Therapy, Lung cancer, Cisplatin, PFS, European Society for Medical Oncology, Phenotype, Research, TIL, JCO, Journal, Samsung Medical Center, ALK, Journal of Clinical Oncology, Annual general meeting, Immunotherapy, H&E, ORR, Oncology, ABCP, Mutation, EGFR, Pharmaceutical industry, Medical imaging

Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO.

Key Points: 
  • Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO.
  • Lunit SCOPE IO, an AI-powered TIL analyzer for assessing immune phenotype from H&E, played a pivotal role in this research.
  • Immune phenotype as assessed by Lunit SCOPE IO showed predictive power in stratifying patients more likely to respond to ABCP treatment.
  • "We aim for Lunit SCOPE IO to continue to make immune phenotyping a quantitative biomarker readily accessible for research, clinical use, and companion diagnostics (CDx) business."

U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, October 12, 2023
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Annual general meeting, Constipation, JCO, Fatal, Arrhythmia, Joint Planning and Development Office, NYSE, Lung cancer, Food, Cetuximab, Myocardial infarction, Memorial Sloan Kettering Cancer Center, IRC, Plasma, Vomiting, NSCLC, Bleeding, Cough, Anemia, BRAF, Pfizer, ORR, Inc., Society, American Society of Clinical Oncology, Mutation, CRC, Disease, Diarrhea, Abdominal pain, Visual impairment, DSM-IV codes, Nausea, Rash, Periodic breathing, Journal, Fatigue, DOR, Pneumonia, Intracranial hemorrhage, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American Journal of Clinical Oncology, MSK, ASCO, Pleural effusion, Edema, Patient, PFE, Risk, Pharmaceutical industry

“Today’s approval builds on our long-standing commitment to deliver innovative, personalized medicines to patients with lung cancer.

Key Points: 
  • “Today’s approval builds on our long-standing commitment to deliver innovative, personalized medicines to patients with lung cancer.
  • “The PHAROS trial demonstrated that these patients could benefit from BRAFTOVI + MEKTOVI targeted therapy regardless of their prior treatment history.
  • BRAFTOVI + MEKTOVI is also FDA-approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
  • BRAFTOVI is FDA-approved, in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

H2O Innovation Reports Fiscal Year 2023 Results - Maintained Growth Momentum and Strengthened Financial Position

Retrieved on: 
Wednesday, September 27, 2023
Engineering, Other Natural Resources, Utilities, Environment, Manufacturing, Natural Resources, Energy, Pressure, SG, Investment, Marketing, Bank statement, GAAP, JCO, Calumet Specialty Products Partners, EBITDA, Corporation, Acquisition, Nature, Generally Accepted Accounting Principles (United States), O&M, Depreciation, Growth, Weather, EC, WTS, Clothing, Bank

Specialty Products’ business pillar delivered components and consumables to large desalination plants and penetrated strategic regions in the Middle East during the third quarter of fiscal year 2023.

Key Points: 
  • Specialty Products’ business pillar delivered components and consumables to large desalination plants and penetrated strategic regions in the Middle East during the third quarter of fiscal year 2023.
  • This momentum was sustained during the fourth quarter of fiscal year 2023 with a breakthrough in the Israeli market.
  • Specialty Products’ EBAC2 increased by $3.1 M, or 20.4%, representing an increase in dollars, but a decrease in percentage over revenues.
  • However, these measures should not be viewed as a substitute for related financial information prepared in accordance with IFRS.

UST Vision Checkout AI-Enabled Autonomous Retail Solution Implemented at Jackson Hole Airport Restaurant

Retrieved on: 
Thursday, September 21, 2023
Cloud, Rhea, Food, UI, Shoplifting, Jedediah Smith, POS, Microsoft, JCO, Airport, Xeon, Commerce, SKU, Jackson Hole Airport, Intel, AI, ROI, SVP, Bistro, Micro, Temple of Azure Clouds, UST, SCO, Software, Online shopping

ALISO VIEJO, Calif., Sept. 21, 2023 /PRNewswire/ -- UST, a leading digital transformation solutions company, is proud to announce that UST Vision Checkout – a frictionless, touchless retail solution designed to streamline the shopping experience – has been deployed at Jackson Hole Airport (JCO) in Wyoming, U.S. The innovative solution is located at the Bistro and Grab & Go areas of Jedediah's at the Airport, the sole food vendor at an airport that welcomes over 500,000 passengers annually. UST is a leading innovator in frictionless commerce, offering advanced retail solutions that accelerate the digital transformation of traditional brick-and-mortar stores and equip them for future success.

Key Points: 
  • UST Vision Checkout is part of UST's comprehensive retail solution offerings and is a SCO (Self-checkout) terminal powered by computer vision.
  • "UST Vision Checkout makes checkout up to three times faster, meaning it is a win-win for retail operators and customers.
  • With its advanced item training options and onboarding capability, UST Vision Checkout is an AI-based end-to-end retail solution that can be quickly integrated into any retail setting.
  • For more information on UST and its work driving digital innovation, please visit the homepage of UST Retail and the UST Newsroom .

Northwest Oncology & Hematology Partners with Canopy to Enhance Operations for Continuous Care Management

Retrieved on: 
Tuesday, September 19, 2023
Partnership, NCCA, Program management, Nursing, JCO, ASCO, Triage, EHR, Patient, Health, Hematology, Canopy

NEW YORK, Sept. 19, 2023 /PRNewswire/ -- Northwest Oncology & Hematology (NWOH), a QOPI-certified practice and member of the National Cancer Care Alliance (NCCA) , today announced a partnership with Canopy , the first Intelligent Care Platform for oncology.

Key Points: 
  • NEW YORK, Sept. 19, 2023 /PRNewswire/ -- Northwest Oncology & Hematology (NWOH), a QOPI-certified practice and member of the National Cancer Care Alliance (NCCA) , today announced a partnership with Canopy , the first Intelligent Care Platform for oncology.
  • This partnership aims to further enhance patient outcomes by streamlining operations for continuous care delivery, as well as maximize the benefit of reimbursement programs like Chronic and Principal Care Management (CCM/PCM).
  • "Northwest Oncology & Hematology is committed to providing the highest-quality care, which means being there for patients and their families when they're away from the clinic," said Kimberly Hunt, Chief Operating Officer of Northwest Oncology & Hematology.
  • NWOH is also implementing Chronic and Principal Care Management (CCM/PCM) to support continuous care efforts and other quality care initiatives.

New York Cancer & Blood Specialists Partners with Canopy to Enhance Patient Outcomes Through Continuous Care Management

Retrieved on: 
Thursday, September 7, 2023
PCM, Partnership, Centers for Medicare & Medicaid Services, JCO, ASCO, Medicare, CCM, Patient, Principal, Health, Nursing, Canopy

NEW YORK, Sept. 7, 2023 /PRNewswire/ -- New York Cancer & Blood Specialists (NYCBS), one of the nation's leading oncology practices, today announced a partnership with Canopy , the first Intelligent Care Platform for oncology, to further enhance patient outcomes through continuous care management.

Key Points: 
  • NEW YORK, Sept. 7, 2023 /PRNewswire/ -- New York Cancer & Blood Specialists (NYCBS), one of the nation's leading oncology practices, today announced a partnership with Canopy , the first Intelligent Care Platform for oncology, to further enhance patient outcomes through continuous care management.
  • A recognized leader in value-based care, NYCBS has enrolled more than 10,000 patients in high-quality, affordable care programs like Principal and Chronic Care Management (PCM/CCM).
  • These programs are acknowledged by the Centers for Medicare & Medicaid Services for their ability to enhance patient care and outcomes while lowering overall healthcare costs.
  • NYCBS also plans to implement the Canopy ePRO (electronic patient-reported outcomes) to further enhance continuous care and patient outcomes through remote symptom monitoring.

Nexcella Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

Retrieved on: 
Friday, September 1, 2023
Columbia University, Journal of Clinical Oncology, Society, Hematology, Multiple myeloma, Physician, AL amyloidosis, Editorial board, IMS, NewYork-Presbyterian Hospital, SOHO, AstraZeneca, JCO, Trial of the century, Medicine, Journal, Committee, AL, Patient, MD, Amyloidosis, Surgeon, Education, LOS, Editor-in-chief, MD–PhD, Pharmaceutical industry

Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical trials for novel agents.

Key Points: 
  • Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical trials for novel agents.
  • Dr. Lentzsch brings extensive experience focused on new therapeutic agents across AL Amyloidosis and multiple myeloma to Nexcella.
  • “Nexcella is developing an autologous CAR-T with clinical results that are encouraging in relapsed AL Amyloidosis and relapsed multiple myeloma.
  • I am thrilled to join the Nexcella Scientific Advisory Board.”
    “We are delighted to be joined by Dr. Lentzsch on the Nexcella Scientific Advisory Board,” stated Ilya Rachman, MD PhD Executive Chairman of Nexcella.

Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

Retrieved on: 
Friday, September 1, 2023
Columbia University, Journal of Clinical Oncology, Society, Hematology, Multiple myeloma, Physician, AL amyloidosis, Editorial board, IMS, NewYork-Presbyterian Hospital, SOHO, AstraZeneca, JCO, Trial of the century, Medicine, Journal, Committee, AL, MD, Patient, Amyloidosis, Surgeon, Education, LOS, Editor-in-chief, Pharmaceutical industry

Dr. Lentzsch brings extensive experience focused on new therapeutic agents across AL Amyloidosis and multiple myeloma to Nexcella.

Key Points: 
  • Dr. Lentzsch brings extensive experience focused on new therapeutic agents across AL Amyloidosis and multiple myeloma to Nexcella.
  • “I have been fortunate to lead efforts to conduct clinical trials resulting in new treatment options for patients with relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma,” said Dr. Lentzsch.
  • “Nexcella is developing an autologous CAR-T with clinical results that are encouraging in relapsed AL Amyloidosis and relapsed multiple myeloma.
  • She is Associate Editor for JCO and on the Editorial Board for Blood Cancer Discoveries.